Creative Medical Technology Holdings Inc (CELZ)

[johnny smartask]

CELZ Our second autologous bone marrow stem cell procedure for the treatment of degenerative disc disease, termed StemSpine™, is in the process of commercialization.

Our second type of technology is a "universal donor" stem cell that is similar to stem cells developed by Athersys and Mesoblast. In contrast to other universal donor stem cell types, the stem cell developed by Creative Medical Technology Holdings, Inc., termed "AmnioStemTM is derived from amniotic fluid, which possesses a higher ability to regenerate tissues as compared to other stem cell types. Our AmnioStemTM, universal donor stem cell is being developed as a treatment for stroke, with an FDA Investigational New Drug Application (IND) filing planned to initiate clinical trials.

"I am very impressed with the speed, agility, and precision that the team at Creative Medical Technology Holdings has displayed in advancing both autologous and allogeneic stem cell therapies," said Dr. Santosh Kesari, MD, PhD, FANA, FAAN, Director of the Neuroscience Research Center at the Pacific Neuroscience Institute and Member of Creative Medical Technology Holdings, Inc. Scientific Advisory Board. "I look forward to working with the company in advancing its adult stem cell therapy products, which aim to address numerous unmet medical needs."